E. Denicolaï

Glycolipids Recognized by A2B5 Antibody Promote Proliferation, Migration, and Clonogenicity in Glioblastoma Cells

D. Figarella-Branger, R. Berges, R. Appay, 2019, Cancers.

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

F. Bertucci, D. Birnbaum, P. Finetti, 2022, Cancers.

Molecular heterogeneity of glioblastomas: does location matter?

O. Chinot, D. Figarella-Branger, C. Colin, 2015, Oncotarget.

Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening.

O. Chinot, D. Figarella-Branger, P. Metellus, 2014, Experimental cell research.

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma

F. Bertucci, P. Finetti, O. Cabaud, 2023, Cancers.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.

O. Chinot, D. Figarella-Branger, E. Tabouret, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype

F. Bertucci, D. Birnbaum, P. Finetti, 2023, Pharmaceutics.

Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152

D. Figarella-Branger, C. Colin, A. El-Battari, 2016, Cell Death and Disease.

Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo

D. Figarella-Branger, M. Carré, C. Colin, 2014, Oncotarget.